Fundz

Hinge Bio reported raising $30.6 Million in an initial SEC Form D filing, from an offering of $40.8 Million

PRIVATEJan 15, 2025$30.6M of $40.8M raised

Amount Raised

$30.6 Million

$30.6 Million sold, per SEC Form D (first sale Dec 31, 2024)

Round Type

Venture

BurlingameBiotechnologyHealth CareTherapeutics

Quick answer

Hinge Bio raised $30.6 Million in a funding round, dated December 31, 2024. Hinge Bio is based in Burlingame, California, United States.

How much did Hinge Bio raise?
Hinge Bio raised $30.6 Million in a funding round on December 31, 2024.
What does Hinge Bio do?
Hinge Bio is a privately held biotechnology company leveraging its powerful GEM-DIMER™ platform to develop therapeutics that address the problems of inadequate efficacy, resistance and side effects.
Where is Hinge Bio based and how big is it?
Hinge Bio is based in Burlingame, California, United States. Fundz records about 16 employees.
Who are the decision-makers at Hinge Bio?
Fundz holds 1 contact at Hinge Bio. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Therapeutics and Biotechnology around the same time

Companies in the same sectors as Hinge Bio that raised within 45 days of this round, from Fundz verified event records.

  • Bambusa Therapeutics raised $90M (Series A) on February 14, 2025.
  • Eikon Therapeutics raised $351M on February 14, 2025.
  • StemSight raised $2.4M (Seed) on February 14, 2025.
  • Newronika raised $14M (Series B) on February 13, 2025.
  • Junevity raised $10M (Seed) on February 13, 2025.
  • Abcuro raised $200M (Series C) on February 12, 2025.

Who to call at Hinge Bio, and when

A new round usually means Hinge Bio is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Hinge Bio raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Hinge Bio, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Hinge Bio. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Hinge Bio

Location

863 MITTEN ROAD, SUITE 100L

Burlingame, California, United States

About

Hinge Bio is a privately held biotechnology company leveraging its powerful GEM-DIMER™ platform to develop therapeutics that address the problems of inadequate efficacy, resistance and side effects. The GEM-DIMER platform creates multivalent, multispecific antibody-based therapeutics that bind their targets in a novel manner allowing for dramatically enhanced biological activity and unique functionality. The GEM-DIMER technology was invented by Hinge Bio's Chief Scientific Officer, Daniel Capon, Ph.D., who previously was the first to clone and express recombinant Factor VIII (Genentech) and invented Fc-fusion proteins (Genentech) as well as chimeric antigen receptors for T cell therapy/CAR-T (Cell Genesys). Dr. Capon also holds patents on the XenoMouse for the production of fully human antibodies (Abgenix) and the PhenoSense drug susceptibility and resistance test (Monogram Biosciences/LabCorp).

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Hinge Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contacts26 people are listed at Hinge Bio. We don't have their email yet.See plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Hinge Bio's next move

See what Strategic adds

Hinge Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.